Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776510 | 1.00 | ARG1 (0.64) | ARG1DPP4CYP1A2ALOX15CYP2C19 | |
| SCHEMBL26118062 | 1.00 | ARG1 (0.64) | ARG1DPP4CYP1A2ALOX15CYP2C19 | |
| SCHEMBL1034091 | 1.00 | ARG1 (0.64) | ARG1DPP4CYP1A2ALOX15CYP2C19 | |
| SCHEMBL5511790 | 0.89 | ARG1 (0.60) | ARG1DPP4CYP1A2ALOX15CYP2C19 | |
| SCHEMBL3787271 | 0.89 | ARG1 (0.60) | ARG1DPP4CYP1A2ALOX15CYP2C19 | |
| SCHEMBL4867875 | 0.87 | ARG1 (0.58) | ARG1DPP4CYP1A2ALOX15CYP2C19 | |
| SCHEMBL3780786 | 0.87 | ARG1 (0.58) | ARG1DPP4CYP1A2ALOX15CYP2C19 | |
| SCHEMBL7442641 | 0.84 | ARG1 (0.58) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL7411388 | 0.84 | ARG1 (0.58) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 | |
| SCHEMBL3781411 | 0.84 | ARG1 (0.58) | ARG1CYP1A2ALOX15CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590159-B2 | Lincomycin biosynthetic intermediates, method for preparation, and use thereof | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2020-03-17 | — | — | US | disclosed |
| US-9982016-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170313743-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-9745344-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20160194357-A1 | Novel NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-07 | — | — | US | disclosed |
| US-9187525-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9169293-B2 | NPR-B agonists | Shire Orphan Thereapies GmbH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-8551938-B2 | NPR-B agonists | ALCON RESEARCH, LTD. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-05-12 | — | — | US | disclosed |
| US-RE29558-E | Lincomycin analogs | THE UPJOHN COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590159-B2 | Lincomycin biosynthetic intermediates, method for preparation, and use thereof | COASY, DHPS, DCXR | ARG1 4275/4885DPP4 3486/4885CYP1A2 612/4885 |
| US-20170313743-A1 | NPR-B Agonists | NPR1, NPR3, NPBWR1 | ARG1 640/4885DPP4 710/4885CYP1A2 4279/4885 |
| US-20160194357-A1 | Novel NPR-B Agonists | NPR1, NPR3, NPBWR1 | ARG1 680/4885DPP4 683/4885CYP1A2 4306/4885 |
| US-20110112038-A1 | NOVEL NPR-B AGONISTS | NPR1, NPR3, NPBWR1 | ARG1 680/4885DPP4 683/4885CYP1A2 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.